Status:

UNKNOWN

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Lead Sponsor:

Groupe Francophone des Myelodysplasies

Conditions:

Myelodysplastic Syndromes

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

We are evaluating the incidence of significant hematological response, according to IWG criteria including CR, PR or, major HI, (HI-E, Hl-N,or Hl- P), and cytogenetic response of patients diagnosed wi...

Detailed Description

Subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1-21, every 4 weeks. Bone marrow asp...

Eligibility Criteria

Inclusion

  • Age \> 18 years at the time of signing the informed consent form
  • MDS with IPSS scores Int-2 or high with deletion 5q(31)
  • Prior thalidomide allowed
  • Documented diagnosis of MDS (RA, RARS, RAEB, RAEB-T and CMML with WBC \< 13,000/mm3 according to FAB classification) that meets IPSS criteria for intermediate-2 or high-risk disease and has an associated del 5q\[31\] (the deleted chromosomal region must include 5q\[31\]), with or without additional cytogenetic abnormalities

Exclusion

  • Pregnant or lactating females
  • Prior therapy with lenalidomide
  • MDS with IPSS scores low or Int-1
  • Clinical neuropathy of greater than grade 2
  • Proliferative (WBC ≥ 13,000/mL) chronic myelomonocytic leukemia (CMML)
  • Recombinant human erythropoietin (rHuEPO) therapy received within 28 days
  • Use of androgens other than for treating hypogonadism

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

End Date :

October 1 2008

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT00424229

Start Date

October 1 2006

End Date

October 1 2008

Last Update

March 12 2007

Active Locations (11)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (11 locations)

1

CHU Angers

Angers, France, 49033

2

CHRU Hurriez

Lille, France, 59057

3

Hopital Paoli Calmette

Marseille, France, 13273

4

Hopital Hotel Dieu

Nantes, France, 44093

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31] | DecenTrialz